Clinical trials
Locally Advanced Lung Non-Small Cell Carcinoma clinical trials
Below are recruiting locally advanced lung non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 250 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07174908RecruitingPhase 3
New drug combo vs standard therapy for KRAS G12C lung cancer
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Beijing, Beijing MunicipalityAges 18–80 - NCT07183189RecruitingPhase 3
New drug combo vs standard for EGFR-mutated lung cancer
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07198841RecruitingPhase 2
Studying IBI351 plus Cetuximab beta for a type of lung cancer
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07330050RecruitingPhase 2
Combination treatment for advanced lung cancer after immunotherapy failure
This trial tests a combination of WAST Cell therapy and the chemotherapy drug docetaxel for people with advanced non-small cell lung cancer whose cancer progressed after treatment with a PD-1 inhibitor. The goal is to see if this combination can help shrink tumors and extend survival.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT03042221Recruiting
Early re-biopsy to find why tumors survive targeted drugs
This study takes a small tumor sample early after starting targeted treatment (or uses blood if a biopsy isn’t possible) to look for clues—called biomarkers—about why some tumor cells survive. The results may help improve how future patients’ treatments are chosen for certain lung cancer gene mutations.
Aurora, ColoradoAges 18–85 - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
Nanchang, JiangxiAges 18–99
Hear when a new Locally Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced lung non-small cell carcinoma?
- Yes. Clin2 currently lists 250 recruiting locally advanced lung non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced lung non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced lung non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Lung Non-Squamous Non-Small Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.